

# Select Health Quality Provider Program

## OSTEOPOROSIS: MANAGEMENT OF WOMEN WITH A FRACTURE 2026 Quality Measure Reference Guide



### What's Inside

Measure Description .....	2
Allowable Corrections .....	3
Frequently Asked Questions.....	4
Working Your Open Gaps List.....	5

### Related Quick Links

- [Endocrinology Quick Guide](#)
- [Intermountain's Bone Health Care Process Model](#)
- [Report Hub Instructions: Basic User](#)
- [Formatting a Gaps List in Excel](#)
- [Demographic Allowable Corrections](#)



*This measure is included in the Endocrinology Quality Provider Program.*

## Measure Description

<b>Description</b>	The percentage of women ages 67–85 on Select Health Medicare who suffered a fracture and who, in the 180 days (6 months) after a fracture, had <b>EITHER</b> : <ul style="list-style-type: none"> <li>• A bone mineral density (BMD) test; <b>OR</b></li> <li>• A prescription for a drug to treat osteoporosis</li> </ul>
<b>Denominator</b>	Women ages 67–85 who suffered a fracture (fractures of the finger, toe, face, and skull not included in this measure)
<b>Numerator</b>	Members in the denominator who had, within 180 days after a fracture, <b>EITHER</b> : <ul style="list-style-type: none"> <li>• Bone mineral density test (BMD) (see <b>Figure 1</b>); <b>OR</b></li> <li>• Dispensed prescription for a drug to treat osteoporosis (see <b>Figure 2</b>).</li> </ul>
<b>Intake and Measurement Periods</b>	<b>Intake Period:</b> July 1 of the year prior through June 30 of the measurement year <b>Measurement Period:</b> January 1 through December 31 of the measurement year

Figure 1. Bone Mineral Density Tests and Associated Codes

CPT Code	Definition
<b>76977</b>	Ultrasound bone density measurement and interpretation, peripheral site(s), any method
<b>77078</b>	Computed tomography (CT) bone mineral density study of the axial skeleton
<b>77080</b>	Dual-energy X-ray absorptiometry (DXA) bone density study of the axial skeleton
<b>77081</b>	DXA of the appendicular skeleton, such as the wrist, heel, or radius
<b>77085</b>	DXA of the axial skeleton, including a vertebral fracture assessment
<b>77086</b>	Vertebral fracture assessment using DXA

Figure 2. Osteoporosis Medications

Description	Prescription
<b>Bisphosphonates</b>	<ul style="list-style-type: none"> <li>• Alendronate</li> <li>• Ibandronate</li> <li>• Alendronate-cholecalciferol</li> <li>• Risedronate</li> <li>• Zoledronic acid</li> </ul>
<b>Other agents</b>	<ul style="list-style-type: none"> <li>• Abaloparatide</li> <li>• Denosumab</li> <li>• Raloxifene</li> <li>• Romosozumab</li> <li>• Teriparatide</li> </ul>

## Allowable Corrections

---

**There are no allowable corrections for this measure.**

To meet compliance for this measure, the patient requires either a documented claim for a bone mineral density test or confirmation of a dispensed or administered prescription for treatment.

[Access guidance for general corrections to demographics.](#)

## Frequently Asked Questions

### Q: Why does this measure matter?

**A:** Osteoporosis is characterized by low bone mass, which leads to bone fragility and increased susceptibility to fractures of the hip, spine, and wrist. Osteoporotic fractures, particularly hip fractures, are associated with chronic pain and disability, loss of independence, decreased quality of life, and increased mortality. Appropriate screening and treatment can reduce the risk of osteoporosis-related fractures.<sup>1</sup>

### Q: What is Select Health doing to help?

**A:** Outreach to Select Health members includes:

- Emailing and/or faxing provider offices after a woman sustains a fracture
- Sending an email or letter to the member after they sustain a fracture that encourages seeing a provider and **EITHER**:
  - Schedule a bone mineral density (BMD) test; **OR**
  - Request treatment for osteoporosis
- Using an in-home bone health screening provider when appropriate

### Q: What are best practices for this measure?

**A:** Best practices for **treatment** include:

- Referring patients who have had a fracture for BMD testing.\* Follow up with the patient to ensure the test was completed.
- Reminding patients that:
  - Regular bone mineral density (BMD) testing is important for monitoring bone loss over time.
  - Select Health will pay for BMD testing every 24 months.
- Reviewing BMD results and prescribing osteoporosis treatment when appropriate. **NOTE:** If patients are unable or unwilling to have the BMD testing, prescribe osteoporosis medications, if appropriate.

**A:** Best practices for **prevention** include:

- Screening female patients starting at age 65, and every 2 years thereafter, to reduce the risk of osteoporosis
- Discussing fall prevention annually, focusing on:
  - Asking about problems with balance or walking and evaluating the need for an assistive device (e.g., cane, walker) if problems exist
  - Suggesting an exercise or balance program
  - Asking if your patient has fallen in the past 12 months, and if so, what led to the fall
  - Discussing trip hazards (e.g., loose carpets, poor lighting, uneven flooring, and cluttered walkways)
  - Emphasizing prevention measures (e.g., using night lights, wearing supportive shoes with grip or no-slip socks, the benefits of installing grab bars, etc.)
  - Reviewing medications to identify possible side effects or interactions that can increase risk
  - Encouraging annual vision and hearing checks
- Discussing calcium and vitamin D supplements, weight bearing exercises, and modifying risk factors
- Reminding patients to always tell their primary care or endocrinology provider about a fracture, even if they have received treatment for it elsewhere
- Using the Bone Health & Osteoporosis Foundation provider tool kit: [Your Path to Good Bone Health](#)

\* If your patient has sustained a fracture within the last 180 days, please refer to the [Screening Options](#) flyer about DXA scan and covered medications relevant to this measure.

### Reference:

<sup>1</sup> National Council for Quality Assurance (NCQA). *Osteoporosis Management in Women Who Had A Fracture (OMW)*. NCQA.org. 2025. <https://www.ncqa.org/report-cards/health-plans/state-of-health-care-quality-report/osteoporosis-management-in-women-who-had-a-fracture-omw/>  
Accessed December 19, 2025.

## Working Your Open Gaps List

STEP 1
<p>Create a current gaps-in-care list:</p> <ol style="list-style-type: none"> <li>1. Open your Gaps-in-Care-for-Download report: <a href="#">QPP Report Hub</a></li> <li>2. Apply these filters:                             <ul style="list-style-type: none"> <li>— <b>Super clinic:</b> Choose your clinic.</li> <li>— <b>Measure:</b> Click on “Osteoporosis Management.”</li> <li>— <b>Status:</b> Unclick the “Compliant” box. This will filter for only the achievable and missed members.</li> </ul> </li> <li>3. In the drop-down menu on the top right side of the page, change the view from “Member” to “Download.”</li> <li>4. Follow the instructions on the screen to export the data to Excel.</li> </ol> <p>Refer to <a href="#">Report Hub Instructions: Basic User</a>.</p>
STEP 2
Format your Excel export. (Refer to <a href="#">Formatting a Gaps List in Excel</a> .)
STEP 3
Review tips for working your gaps-in-care list (see <a href="#">page 6</a> ).

### Measure Information

According to the Endocrine Society, 1 in 2 postmenopausal women will have an osteoporotic fracture in her lifetime.<sup>1</sup> Those who sustained a fracture are at high risk of subsequent fractures. Osteoporotic fractures, particularly hip fractures, are associated with chronic pain and disability, loss of independence, decreased quality of life, and increased mortality. Appropriate screening and treatment can reduce the risk of osteoporosis-related fractures and improve health outcomes.<sup>2</sup>

**NOTE:** Examples used in this document are for instructional purposes only; the dates that appear are only representative of what a user might see.

**For this measure:**

- **Measurement start date:** Use the “Status Detail” column. **NOTE:** part of the verbiage has been cut off in this column.
- **Measurement end date:** Use the “Measure Instruction” column as it shouldn’t disappear after the date passed.

Measure Name	Qualified Date	Status	Status Detail	Achievable Date	Measure Instructions
Osteoporosis Management (OMW ENDO)	MM/DD/YYYY	Missed	had fracture on MM/DD/YYYY	MM/DD/YYYY	Member needs osteoporosis testing or treatment before MM/DD/YYYY. Schedule testing or treatment.
Osteoporosis Management (OMW ENDO)	MM/DD/YYYY	Achievable	had fracture on MM/DD/YYYY		Member did not receive osteoporosis testing or treatment by MM/DD/YYYY.

Any screening or treatment completed **AFTER** the measurement end date will **NOT** count as compliance for this measure.

## Working Your Open Gaps List, Continued

---

### Tips for Working your Gaps-in-Care List

- 1. If your team hasn't already done so, please implement these best practices:**
  - Create a bone health assessment, treatment and fracture management workflow for post-menopausal women.
  - Designate staff to pull the open gaps list from the [Quality Provider Program Report Hub](#) at least monthly.
- 2. Sort the list using “Achievable Date” column and the oldest-to-newest sorting option.** (For details on how to sort, please refer back to the QPP [Formatting a Gaps in List in Excel](#)). This will sort the list by those whose measurement end period ends first.
- 3. Follow your post-menopausal fracture management workflow.** This may include:
  - Setting a provider alert or note in the member's electronic health record (EHR) regarding the fracture and the need for follow-up care.
  - Once the provider responds with screening or treatment orders, ensure follow-up care with the member is scheduled and completed within 180 days of fracture (measurement end date).
- 4. Corrections. There are no allowable corrections for this measure.** To meet compliance for this measure, the patient requires either a documented claim for a bone mineral density test or confirmation of a dispensed or administered prescription for treatment.

---

### References:

- <sup>1</sup> Estell R et al. Pharmacological management of osteoporosis in postmenopausal women: An Endocrine Society clinical practice guideline. *JECM*. 2020; 105(3):587-594.
- <sup>2</sup> U.S. Preventive Services Task Force. *Final Recommendation Statement: Osteoporosis to Prevent Fractures: Screening*. USPSTF Website. January 14, 2025. <https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/osteoporosis-screening>. Accessed December 19, 2025.

Questions about the Quality Provider Program?  
Contact us at [QualityProvider@selecthealth.org](mailto:QualityProvider@selecthealth.org).